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APOBECs orchestrate genomic and
epigenomic editing across health and disease
Karla Cervantes-Gracia,1,2 Anna Gramalla-Schmitz,1,2 Julian Weischedel,1 and Richard Chahwan 1,*
APOBEC proteins can deaminate cytosine residues in DNA and RNA. This can
lead to somatic mutations, DNA breaks, RNA modifications, or DNA demethyl-
ation in a selective manner. APOBECs function in various cellular compart-
ments and recognize different nucleic acid motifs and structures. They
orchestrate a wide array of genomic and epigenomic modifications, thereby
affecting various cellular functions positively or negatively, including immune
editing, viral and retroelement restriction, DNA damage responses, DNA
demethylation, gene expression, and tissue homeostasis. Furthermore, the
cumulative increase in genomic and epigenomic editing with aging could
also, at least in part, be attributed to APOBEC function. We synthesize our
cumulative understanding of APOBEC activity in a unifying overview and
discuss their genomic and epigenomic impact in physiological, pathological,
and technological contexts.
The pleiotropic roles of cytosine deaminases in genomic and epigenomic editing
Cytosine deamination can modify the genomic code by mediating cytosine to uracil (C-to-U)
conversion, thus creating U:G DNA mismatches that are subsequently consolidated by error-
prone DNA repair processing. Although cytosine deamination can occur spontaneously,
these reactions can be catalyzed by APOBECs (see Glossary) in a regulated process
[1–4]. Almost all APOBECs (with the exception of A3D, A2, and A4) can also edit, with
varying proficiencies, the epigenomic code by deaminating 5-methylcytosine (5mC) to
thymine – creating T:G mismatches – followed by error-free DNA repair [5–9] (Figure 1,
blue). Although most mutations generally have adverse effects on cells and lead to disease
emergence, a few cell types evolved to harness the mutagenic process for positive physio-
logical purposes, particularly during adaptive and innate immunity. Eleven APOBEC proteins
have been described in humans. AID (activation-induced cytosine deaminase) is arguably the
evolutionary founding member and has been extensively studied in the context of somatic
hypermutation (SHM) and class-switch recombination (CSR) during antibody diversifi-
cation [10,11]. APOBECs are also involved in several physiological processes including lipid
metabolism (APOBEC1) [12], musculogenesis (APOBEC2) [13], retroelement restriction
(APOBEC3s) [14], DNA damage (AID, APOBEC3s) [15], and cell homeostasis [16]. Despite
their beneficial roles, dysregulation of APOBECs is associated with several diseases
[17,18]. Signatures of APOBECs feature in many cancer genomes and are considered to
be potent mediators of tumorigenesis [19,20]. Loss-of-function mutations in APOBECs can
also result in immune deficiencies or autoimmunity [7,20,21]. In the following sections
APOBEC family regulation (Figure 1), their genomic and epigenomic mechanisms
(Figure 2), their involvement in physiology and pathology (Figure 3A–H, Key figure), and
their evolutionary and technological applications (Figure 4) are synthesized and discussed
from a unifying perspective.
Highlights
Genomic and epigenomic effects of apo-
lipoprotein B mRNA editing cytosine de-
aminases (APOBECs) are tightly
controlled and are essential for physio-
logical immune and non-immune
processes.
Pathological APOBEC off-target effects
are often observed because of altered
catalytic activity or dysregulation, and/or
synergies with other predisposing fac-
tors such as infections, inflammation, or
DNA repair defects.
APOBEC mutation signatures are docu-
mented in various cancers. They are also
involved in autoimmune diseases, triple
nucleotide repeat diseases, and diabe-
tes, among others.
Possible APOBEC signatures in aging
tissues also highlight their potential con-
tribution to this process at the genomic
and epigenomic levels.
Advances in gene-editing technologies
combined with APOBEC mechanistic
insights are ushering in the era of
APOBECs as therapeutic targets, poten-
tially closing the loop of negative versus
positive gene-editing effects.
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APOBEC regulation: from protein domains to catalytic substrates andmodulators
APOBEC catalytic activity is modulated by their ability to bind preferentially to nucleic acid
substrates and motif signatures (WRC for AID and TC for most others); this mode of regulation
could be considered as regulation by 'cis-determinants'. For the APOBEC3 (A3) subfamily it
has been reported that both catalytic and non-catalytic domains interact with single-stranded
DNA (ssDNA) [22]. This regulates substrate deamination by guiding them to active sites in mono-
meric or multimeric conformations. Within the catalytic domains, positive patches distal to the
active sites interact with ssDNA. In the A3F and A3G subtypes, these are reported to be crucial











































































































































































































































































































































































































































Figure 1. Protein and substrate-based regulation of APOBECs and their substrate-like modulators. The protein-
based (green) activities of APOBECs can be regulated through protein expression, degradation, and cell localization.
APOBECs can be further influenced by protein–protein interactions and post-translational modifications. Moreover, the
properties (secondary structure, sequence, DNA and post-transcriptional modifications) and the availability of the substrate
regulate the APOBEC proteins (blue). The importance of substrate-like modulators was recently discovered (orange),
whereby these can bind at the catalytic center or at secondary non-catalytic domains (for A3B, A3D, A3F, A3G) to activate,
inhibit, or guide the APOBEC deaminases. In the center, the dual catalytic and scaffolding functions of APOBEC are
represented by blue and green shades, respectively. Abbreviations: A1, APOBEC1; A2, APOBEC2; A3A-H, APOBEC3A-H;
5hmC, 5-hydroxymethylcytosine; 5hmU, 5-hydroxymethyluracil; 1mA, N1-methyladenosine; 6mA, N6-methyladenosine;
5mC, 5-methylcytosine; ncRNA, non-coding RNA; vRNA, viral RNA. Nucleotides are depicted as N: A, T, G, or C; R: A or G;
W: A or T.
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Glossary
Adenosine deaminase (ADAR): edits
adenosines in double-stranded (ds)
RNA and DNA.
APOBECs: apolipoprotein B mRNA
editing cytosine deaminase family.
APOBECs include activation-induced
cytidine deaminase (AID), APOBEC1
(A1), APOBEC2 (A2), APOBEC3 (A3;
comprising seven subfamily members –
A3A, A3B, A3C, A3D, A3F, A3G, A3H),
and APOBEC4 (A4).
Class-switch recombination (CSR):
a DNA recombination process in
proliferating B cells that is initiated by AID
deamination of intronic areas called
switch (S) regions to produce antibodies
with different properties. The constant
region genes of the immunoglobulin
heavy-chain locus rearrange and switch
from one class to another.
DNA-damage response (DDR):
processes by which a cell identifies,
tags, and promotes the repair of DNA
lesions.
DNA/RNA hybrids: hybrid double helix
helices formed by one DNA and one
RNA strand.
Double Double-strand breaks
(DSBs): DNA lesions generated when
strand breaks occur in dsDNA at nearby
sites because neither base-pairing nor
chromatin structure can keep the DNA
ends juxtaposed.
G4 quadruplex: a DNA or RNA tetrad
secondary structure that is found in
guanine-rich sequences.
5-Hydroxymethylcytosine (5hmC):
the oxidized form of 5mC in DNA, and a
stable epigenetic mark that is crucial for
gene regulation.
Kataegis: patterns of local
hypermutation that are clustered in
specific hotspots in the genome.
Long interspersed nuclear element
1 (LINE-1): class I transposable
elements that account for 17% of the
human genome; they contain two open
reading frames (ORF1 and ORF2) that
are required for LINE-1
retrotransposition.
5-Methylcytosine (5mC): an
epigenetic hallmark that influences DNA
remodeling during mammalian
development and cell differentiation.
5mC is also involved in tumorigenesis.
Mismatch repair (MMR): a
mechanism that identifies and corrects
spontaneous insertions, deletions, and
misincorporations of bases mainly
generated through DNA replication,
thereby maintaining genome stability.
are important to boost deamination by A3F, A3G, and A3B [22] (Figure 1). However, catalytic
domains on their own have inconsistent deaminase activity, and the non-catalytic domains there-
fore have an important regulatory role.
APOBECs also have a preference for specific motif sequences and substrate structures. AID
preferentially binds to and targets DNA G4 quadruplex structures during transcription [24].
G4-RNA (from transcribed switch regions) is indispensable to direct AID to its corresponding
switch-region (S) target site. During CSR, ssDNA is formed by the R-loop generated through
the action of RNA helicase DDX1, leading to RNA:DNA post-transcriptional events [25]. It has
been suggested that AID multimerizes during CSR when interacting with G4 structures [24].
The ribonucleoprotein (RNP) binding proteins, HnRNP-K and -L, have been proposed as
cofactors that support and regulate AID deamination during SHM and CSR [26]. The affinity of
A3A is also higher for DNA and RNA hairpins [27].
By contrast, an inhibitory role has been attributed to RNA structures bound to the A3G, A3H, and
AID catalytic domains. The action of RNase has long been described as being crucial for AID
ssDNA deamination [28]. RNA binding promotes the dissociation of A3G multimers and restricts








































































































Figure 2. Genomic and epigenomic mechanisms of APOBEC deamination. APOBEC deaminases target DNA
(blue) or RNA (green) substrates, leading to genetic (blue shading) or epigenetic changes (green shading). Both are known
to be involved in healthy/physiological or disease/pathological processes. Abbreviations: HR, homologous recombination;
NHEJ, non-homologous end joining; RT, reverse transcriptase. Nucleotides are depicted as N: A, C, G, or T; H: A, C, or T;
R: A or G; W: A or T; Y: C or T.
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compartments with antiviral and
potential anticancer properties.
R-loop: a triple-stranded byproduct of
transcription comprising an RNA–DNA
hybrid and the non-template single-
stranded (ss) DNA.
Retroelements: DNA sequences that
integrate into the genome after copying
an RNA genome into DNA by reverse
transcriptase (RT).
Ribonucleoproteins (RNP): RNA and
RNA-binding protein complexes that are
essential in transcription, translation,
gene expression regulation, and RNA
metabolism.
Single-base substitution (SBS):
reference mutational signature patterns
identified by the COSMIC database.
There are currently about 94 such
signatures, SBS1–94.
Somatic hypermutation (SHM): a
process initiated by AID deamination
that promotes the accumulation of
mutations in the V region of the heavy
and light chains of immunoglobulin
genes, following by controlled selection
of high-affinity antibodies in the germinal
center of secondary lymphoid organs.
Switch region (S-region): intronic
areas targeted by AID, uracil-DNA
glycosylase (UNG), and apurinic-




enzymes that catalyze the conversion of
5mC to 5hmC in DNA; family members
are TET1, TET2, TET3.
Viral infectivity factor (Vif): a viral
protein found in HIV and other
lentiviruses; its main function is to control
the immune response by counteracting
APOBECs.
RNA binding to A3H also inhibits and regulates its deaminase activity [29] (Figure 1). Notably, RNA
binding to A3H loops 1 and 7 (adjacent to the A3H catalytic pocket) changes A3H structure. Res-
idues from these loops are known to regulate 5mC deamination by A3A and A3G [30]. In A3H, it is
proposed that RNA must be released from loops 1 and 7 for the enzyme to identify, bind to, and
deaminate ssDNA/mC [31].
Key figure
The pleiotropic role of cytosine deaminases
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Figure 3. The APOBEC cytosine deaminase family members act at the genomic (blue) and epigenomic (green) levels. The
deaminases are involved in many immune (lighter shades) and non-immune (darker shades) physiological (yellow)
processes. When dysregulated, however, these enzymes can lead to various pathologies (orange). The APOBEC
functions and effects are depicted in eight parts (A–H). (A) Genomic immune physiology. (B) Genomic non-immune
physiology. (C) Genomic non-immune pathology. (D) Genomic immune pathology. (E) Epigenomic immune pathology. (F)
Epigenomic non-immune pathology. (G) Epigenomic non-immune physiology. (H) Epigenomic immune physiology.
Abbreviations: CSR, class-switch recombination; DSB, double-strand break; gDNA, genomic DNA; 5mC, 5-
methylcytosine; miRNA, microRNA; mtDNA, mitochondrial DNA; ROS, reactive oxygen species; RT, reverse transcription;
SHM, somatic hypermutation; vDNA, viral DNA.
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Phosphorylation is also considered to be an important APOBEC post-translational modulator.
Phosphorylation of AID Ser38 residue promotes CSR; it is essential for AID and replication protein
A complex 2 (RPA2) binding (Figure 1). By contrast, Thr27 phosphorylation inhibits its deaminase
activity [32]. The same outcome has been described for A3B Thr214 and A3G Thr218 phosphor-
ylation [33]. Furthermore, Thr32 phosphorylation reduces A3G affinity for HIV viral infectivity
factor (Vif), decreasing its degradation rate [34], highlighting the importance of the dual roles
of phosphorylation in APOBECs.
APOBEC induction can also depend on 'trans-determinants'. APOBEC often depends on envi-
ronmental factors, which occur transiently throughout a lifetime, leading to the accumulation of
what is now termed 'episodic' rather than consistent mutational APOBEC events [35]. Proinflam-










































Figure 4. Evolutionarily and technologically driven gene-editing applications of APOBECs. (A) Different complexity
levels of coevolution driven by APOBEC deaminases, DDR, and selective pressure over time. (B) A perspective of APOBECs
as corrective and preventive tools to treat diseases at the genomic and epigenomic levels. Abbreviations: DDR, DNA damage
response; TME, tumor microenvironment.
Trends in Genetics
OPEN ACCESS
1032 Trends in Genetics, November 2021, Vol. 37, No. 11
Moreover, alternative splicing can also control APOBEC function through the generation of
isoforms (e.g., A3A, B, H, and F). A3B splice variants can restrain mutagenic A3B1 expression
[36]. A3H function can be diversified by alternative splicing into three isoforms: non-functional,
maintained function, and enhanced viral restriction function [37].
The localization of APOBECs is another important factor that regulates their activity. They tend to be
localized either within the cytoplasm or the nucleus. Thus, cytoplasmic signals (e.g., for A1, AID) or
viral byproducts (e.g., for A3G) can regulate APOBEC activity. In addition, heat-shock proteins
(Hsp70/90) can also stabilize AID in the cytoplasm by inhibiting its ubiquitylation and proteasomal
degradation [38]. USP49 was also reported to stabilize A3G by hindering and removing the HIV
Vif A3G ubiquitination mark, thereby enhancing A3G activity [39]. APOBECs can also be enclosed
in P-bodies (e.g., A3G and F). A3G association in large RNP complexes suppresses its catalytic
activity, but a moderate increase in A3G expression was found to decrease the formation of pro-
cessing bodies (P-bodies) and promote stress-resistance [40]. Recent data suggest that
depletion of exosome component 9 (EXOSC9; P-body formation factor) induces A3G over-
expression, thus aiding APOBEC regulation positively [40].
In parallel, inhibition of long interspersed nuclear repeat 1 (LINE-1) and endogenous retro-
virus (ERV) retroelements through G-to-A hypermutation has been long attributed to A3s
(Figures 2 and 3B). Thus, the cofactors for APOBECs involved in retroelement restriction are
also of interest. RPA is involved in LINE-1-retroelement integration and protects ssDNA during
target-site primer reverse transcription from deamination in vitro, but its recent association with
A3A suggests that RPA guides them both to integration sites and restricts retrotransposition
[41]. A3C, A3D/E, and A3H also restrict retrotransposition, the former by creating dimers
and all by interacting with LINE-1 ORF1p in an RNA-dependent manner, suggesting interplay
with LINE-1 RNP [42]. In addition, extracellular vesicles secreted by cells expressing A3G
and A3F can also restrict retrotransposition [43] (Figure 1, green).
Genomic and epigenomic contributions of APOBECs to immune physiology
Several APOBECs belong to the class of IFN response genes and are upregulated upon pathogen
encounter in immune and non-immune cells. In adaptive and innate immunity, they act at both the
genomic and epigenomic levels.
In germinal center B cells, AID is upregulated and mediates SHM and CSR of immunoglobulin
genes. Thus, AID producesmutations and double-strand breaks (DSBs) in DNA, which enables
B cells to produce functional and high-affinity antibodies against pathogens (Figures 2 and 3A)
(reviewed in [44]). AID alsomediates DNA demethylation and increases methylation diversity during
the differentiation of naïve B cells in germinal centers [45]. Although these results indicate a
contribution of AID deaminase activity, direct proof of AID involvement remains elusive. Further
epigenomic changes are attributed to the APOBEC A3A and A3G, which facilitate antiviral cell
responses by editing host and pathogen RNAs (Figure 3H). A3A was reported to deaminate
several host mRNAs to promote proinflammatory (M1) macrophage polarization activated by
viral infection, IFN, and hypoxia [46] (Figure 3H). Moreover, A3A and A3G host mRNA editing
leads to altered levels of cellular proteins which are required for a successful viral life cycle [47].
However, a direct connection between the host RNA editing and the virus-restricting and proin-
flammatory functions of A3A remains to be fully elucidated.
APOBEC deaminases further restrict DNA viruses and retroviruses directly in an editing-
dependent manner (extensively reviewed in [48]) (Figure 3A). Recently, studies on coronaviruses
(CoVs) and rubella also indicated an involvement of APOBECs in RNA virus restriction. A study on
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human CoV-NL63 showed inhibition of virus replication mediated by A3C, A3F, and A3H, but
could not detect hypermutation of the RNA genome in in vitro assays [49]. However, the RNA
genome of coronaviruses is highly U/A-rich [50], and mutation analysis of severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) virus shows predominant C-to-U transitions in
which UCN hotspot motifs are preferentially targeted [51,52]. Interestingly, RNA viruses in
invertebrates – where APOBECs are absent – do not manifest a marked increase in C-to-U
mutations [53,54]. Furthermore, analysis of the RNA secondary structure elements surrounding
the mutated Cs strongly indicate A3A as a potential candidate [51]. Rigorous high-resolution
sequencing of SARS-CoV-2 during the pandemic provides a large number of accurate virus
genome sequences that enable real-time monitoring of virus–host evolution. The contribution of
APOBECs to host–virus coevolution is under investigation, and whether APOBEC-induced
mutations contribute to immune escape or drug resistance of the virus has been debated (Box 1).
Apart from APOBEC-mediated virus genome editing, various publications report deamination-
independent restriction mechanisms, and APOBECs may therefore interfere with the replication
and transcription of viral genomes by binding to viral proteins and RNAs or by blocking viral
polymerases (reviewed in [48]).
Genomic and epigenomic contributions of APOBECs to immune pathology
APOBEC deaminases are also widely associated with immune-related diseases ranging from
autoimmune diseases to immune cell-derived cancer and virus-associated cancers. Individuals
with germline mutations in the AICDA gene develop a hyper-IgM syndrome (Figure 3D). They
display decreased serum IgG and IgA concentrations and normal or elevated IgM levels, which
subsequently lead to increased susceptibility to infections (reviewed in [55]). Furthermore,
Box 1. The contribution of APOBEC to host–virus coevolution
Viruses are predicted to have fewer APOBEC motifs in their genomes because of innate immune APOBEC deaminase
editing of viral genomes over a protracted evolutionary timescale (see Figure 4A in main text). APOBECs have varying tar-
get sequence biases (see Figure 1 in main text); therefore, reduced APOBECmotif representations might differ depending
on each virus. For example, γ-herpesviruses EBV and Kaposi sarcoma-associated herpesvirus (KSHV) exhibit a reduction
in 5′-TCmotifs that are preferentially edited by A3A/B [119]. By contrast, 5′-CCCmotifs which are edited by A3G are over-
represented, albeit not hypermutated [119]. Herpesvirus genomes might be protected from A3G editing because A3G
(i) preferentially edits retroviruses, and (ii) is mainly located in the cytoplasm; it therefore might not be recruited and
incorporated into virions. However, viruses cannot completely avoid APOBEC target motifs, especially in functionally
important sequences. Therefore, some viruses have evolved proteins or miRNAs to inhibit, block, or sequester APOBEC
proteins or to downregulate their expression. For instance, HIV Vif was demonstrated to mark A3 enzymes for degradation
as well as to interfere with A3G transcription and translation [120]. More recently, it was shown that the EBV and KSHV
relocalize A3B and A3A into cytoplasmic aggregates with their ribonucleotide reductase proteins BORF2 and ORF61,
respectively, to prevent disadvantageous mutations in the viral genome (reviewed in [18]).
There is ongoing debate, especially for HIV, about whether APOBEC-inducedmutations can contribute to immune escape
or drug resistance of the virus. Some studies have postulated an 'all-or-nothing' phenomenon for A3G and HIV
interactions, whereby therapy resistance mediated by A3G is excluded [121]. However, incomplete suppression of A3s
by less potent HIV Vif mutants may enable sublethal A3 mutagenesis of the virus and might lead to advantageous viral
heterogeneity [122]. An in vivo study investigating A3G-mediated HIV drug resistance in humanized mice showed that
mice infected with HIV Vif mutants differ in their ability to counteract A3G when treated with an antiretroviral monotherapy
to increase the selection pressure. However, moderate A3G activity still led to attenuation of the virus in the absence of
selection, suggesting a fitness advantage in the presence of antiretroviral therapy [123]. Moreover, the analysis of all potential
cytotoxic T lymphocyte (CTL) epitopes in HIV Gag, Pol, Env, and Nef showed that non-lethal A3G-mediatedmutations overall
result in decreased HLA binding affinities [124]. The lower affinity further leads to CTL escape rather than to more immuno-
genic epitopes [124]. In addition, non-lethal APOBEC-mediated editing of long terminal repeat (LTR)-retrotransposons was
also proposed to be a source of host genome evolution. Integrated retrotransposons are over-represented in genes, exons,
promoters, and transcription start-sites, and might be utilized for additional genomic functions [125]. In summary, years of
evolution have led to a multifaceted and complex APOBEC–virus interaction which offers insights for further broader
investigations into host–pathogen coevolution (see Figure 4A in main text).
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patients with homozygous or heterozygous AICDA germline mutations are also unable to prevent
the accumulation of autoreactive mature IgM B cells and their regulatory T cells show defective
suppression capacity [56]. AID expression during early B cell development is important for self-
tolerance and suppression of auto-IgM antibodies.
APOBEC deaminases have also shown to contribute epigenetically to autoimmune diseases
such as systemic lupus erythematosus (SLE) [57] and primary Sjörgren's syndrome (SS) [58].
Epigenomic modifications play a crucial role in autoimmunity, and hypomethylation was demon-
strated to increase LINE-1 endogenous retroelements in SLE and SS [59] (Figure 2). In minor
salivary gland tissue from SS patients, increased LINE-1 retroelement and interferon levels
were shown to correlate with elevated expression of A3A, A3G, and AICDA genes [58]. The
same was observed in kidney tissue and peripheral blood mononuclear cells of SLE patients
for A3A [58]. In addition, high-throughput sequencing data from SLE patients reveal high global
APOBEC expression, which might be a source for autoantigens in SLE [21] (Figure 3E). Because
some APOBECs are reported to contribute to demethylation, their upregulation might further
enhance global hypomethylation in autoimmune diseases (Figure 2).
Even though AID is tightly regulated (Figure 1), and efficient repair mechanisms are in place, AID
is known to contribute to B cell lymphomagenesis. Chromosomal translocations in B cell
lymphomas are associated with and are partly initiated by AID-induced DSBs (reviewed in [60]). Fur-
thermore, large-scale DNA sequencing data from lymphoid tissue of Aicda−/− orMsh−/−Ung−/−mice
compared to control mice revealed that 25% of the expressed genes analyzed are not fully protected
from aberrant AID-mediated SHM (Figures 2 and 3D) [61,62]. Within the AID mutated non-Ig genes,
many lymphoma genes including BCL6, RHOH, PIM1, EBF1, EIF4A2, and PAX5 have been identi-
fied [61,62].
AID global demethylation is proposed to confer an undifferentiated state, similar to that of
methylation factors in cancer, which promotes poorly differentiated tumors and low survival
rates (Figures 2 and 3E–G). AID can deaminate 5mC and 5-hydoxymethylcytosine (5hmC)
(reviewed by [63]). AID demethylation of germinal center B cells cytosines is believed to exacer-
bate intra- and intertumor plasticity in non-Hodgkin lymphomas. Overexpression of AID in mice
showed increased AID-induced methylation heterogeneity in aggressive activated B cell-like dif-
fuse large B cell lymphomas (ABC-DLBCLs) [64]. Interestingly, epigenomic modulators are
frequently mutated in DLBCL (reviewed in [60]). In chronic lymphocytic leukemia (CLL) it has
also been proposed that AID demethylation correlates with worse clinical prognosis [65]. Whether
AID contributes directly or indirectly to demethylation and further epigenetic changes is still under
investigation. In DLBCL cell lines, it was demonstrated that AID cooperates with the ten-eleven
translocation (TET) enzyme TET2 to demethylate the proto-oncogene, Fanconi anemia
complementation group A (FANCA), followed by its increased expression [66]. Moreover,
AID has recently been identified to display an alternative cofactor role by assisting DNA
(cytosine-5)-methyltransferase 1 (DNMT1). The AID–DNMT1 complex preserves BCL6 proto-
oncogene repression via promoter methylation, hence promoting negative regulation of BCL6
transcription [67].
The role of APOBEC in virus-derived cancer remains unclear and has recently become the
focus of attention. It is debatable, however, whether APOBEC-mediated mutagenesis con-
tributes to driver and/or passenger mutations. Of all cancers, 16% are estimated to be
virus-associated [68] and APOBEC single-base substitution (SBS) mutation signatures
SBS2 and SBS13 are more abundant in some virus-positive cancers than in virus-negative
cancers (Figure 3D). This has been shown for human papillomavirus (HPV)-positive head
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neck squamous cell carcinoma (HNSCC) which, compared to HPV-negative HNSCC, has el-
evated levels of APOBEC-derived mutation signatures and A3B expression [68,69]. On the
one hand, it was demonstrated that driver mutations in the HNSCC oncogene PIK3CA are
caused by A3B [69]. Nonetheless, these PIK3CA mutations also occur in HPV-negative
HNSCC and are not exclusively linked to viral infections. In alphapapillomavirus-derived
cervix and head/neck cancer the oncogenes TP53, CDKN2A, TERT, FAT1 have significantly
fewer driver mutations compared to virus-negative cancer [68]. In sporadic and endemic
Burkitt's lymphomas, the presence of Epstein–Barr virus (EBV) was linked to an increase
in the overall mutation load, and specifically in mutations attributed to AID, polymerase η
(SBS9), and mismatch repair (MMR) failure (SBS15) [70]. Interestingly, EBV-positive
compared to EBV-negative Burkitt's lymphoma harbor fewer driver mutations in B cell
lymphoma-associated genes [70]. In general, this decrease in driver mutations in cancer-
specific genes could be because viral proteins already fulfill key functions for tumor cell pro-
liferation. Hence, tumorigenesis in virus-derived cancer must be considered differently and
might not follow the same development as other cancers.
Genomic and epigenomic contributions of APOBECs to non-immune physiology
Physiological processes to which APOBECs contribute include hypermutating host and
mitochondrial (mtDNA) genomes (Figure 3B). A3A genomic DNA deamination acts as a warning
system by promoting the production of reactive oxygen species (ROS) and activating NADPH
oxidases and the DNA damage response (DDR). Interestingly, AID and A3s preferentially
deaminate cytosines within damaged motifs, and at the same time oxidized bases feed this
loop by promoting ssDNA availability [15,71]. A3A has also been shown to deaminate and
hypermutate mtDNA released into the circulation by cell disruption, thus promoting catabolism
and homeostasis [16,72] (Figure 3B). During cell differentiation, AID 5-methylcytosine deamina-
tion can stabilize myeloid and erythroid stem cell pluripotent phenotypes [73]. It can also maintain
global demethylation and regulate cell differentiation in a deaminase-independent manner by
downregulating UHRF, thus ensuringmethylationmaintenance during reprogramming processes
[74] (Figures 2 and 3G).
The first APOBEC to be described was APOBEC1 (A1) through its ability to edit the mRNA
encoding APOB protein, thereby producing an isoform involved in lipid metabolism [12,75].
However, A1 has also shown to be involve in demethylation events, for example A1 promotes
nestin demethylation. N-methyl-D-aspartate neurotoxicity induces nestin participation in the
maintenance and self-renewal of Müller cells (MCs) [76] (Figures 2 and 3G). Interestingly, under
neurotoxicity, MCs in mammalian retina present a limited capacity to dedifferentiate, proliferate,
andmigrate to the injured regions (reviewed in [77]), suggesting A1 involvement inMC regeneration.
A1 can also modulate transcriptomic diversification by editing RNAs involved in the regulation and
maintenance of immune cell homeostasis, monocyte cytokine signaling/migration (e.g., RAK1/2),
and maturation/phagocytosis (e.g., LAMP1/2) [78] (Figure 3G).
A3B expression was recently reported to promote cell cycle arrest by disrupting CDK4-
dependent import of cyclin D1 because of a shared binding site on CDK4 [79] (Figure 1). This
insight provides a novel post-translational function for A3B. A3 is also believed to negatively
regulate mouse keratinocyte differentiation by inhibiting Notch3 expression; however ,the exact
mechanism involved remains unknown [80].
Genomic and epigenomic contributions of APOBECs to non-immune pathology
A3s can induce genomic stress and the accumulation of mutational fingerprints that might lead to
disease evolution in proinflammatory states, which in turn induce A3s and create a never-ending
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loop of cell damage [71]. The deamination of A3s can also initiate ROS production, which induces
their hypermutation and promotes a tumor-favorable environment (Figure 3C).
Mutational clusters in tumors, known as kataegis and omikli, have also been attributed to
APOBECs [81]. Among the many DDR mechanisms, MMR activity in gene-rich regions has
been recently suggested to provide ssDNA substrates for A3s and might explain the greater
impact and presence of unclustered signatures of APOBECs in cancer versus conventional
carcinogens (smoke, UV, etc.) [81]. Thus, by processing mismatches occurring during replication,
MMR is proposed to consolidate and enhance mutagenesis of APOBECs, akin to its role in
antibody diversification. DNA damage feed-forward loops generated by A3A and A3B in response
to inhibition of ataxia telangiectasia and Rad3-related (ATR) protein are responsible for sensing
DNA damage and activating DDR pathways [82]. In myeloma cells, A3B continuously promotes
DSBs and activates DDR pathways [83] (Figure 2). DNA damage induced by conventional
anticancer treatments and replication stress has been recently reported to intensify A3B expression
[84]. The latter promotes a positive A3B expression loop that might lead to chemoresistant cells
and promote cancer progression.
Interestingly, deamination of 5mC is known to be regulated by oxidative stress in cancer, cardio-
vascular diseases, and diabetes, and SOD2 overexpression was recently shown to modulate
A3A activity, correlating deamination with oxidative stress [85–87]. A3A/G (C-to-U) has been
recently proposed to mediate RNA-editing events that modify miRNA function in CLL [88]
(Figure 2). More recently, C-to-T A3C-mediated hypermutation was reported to promote the ex-
pansion and evolution of pre-leukemic stem cells (pre-LSCs) into LSCs and secondary acute my-
eloid leukemia in response to an inflammatory microenvironment [20]. In epileptic patients and
other neurotransmitter diseases, C-to-U A1 RNA editing also appears to be of importance be-
cause of its accumulation in glycine receptor mRNA [89] (Figure 2).
APOBECs restriction of retroelements has recently been associated with both potentiation and
protection against viral infection/maintenance and with promoting carcinogenesis. Despite
reports that human retroelements may play a role in carcinogenesis, these elements have also
been associated with the induction of anticancer immunity – the latter through the expression
of viral epitopes that can potentially drive immune responses (Box 1) [90]. Despite APOBEC pro-
tection from excessive genome instability resulting from retrotransposition, it has been proposed
that APOBEC mutagenesis may generate stability in tumor cells, protect virus-infected cells, and
restrict host immune responses driven by retrotransposition [91]. Retroelement activation can
promote innate and adaptive immune signaling as a response to commensal colonization,
pathogen infection, or cellular transformation to maintain cellular integrity [92]. Furthermore, dou-
ble-stranded (ds)RNA retroelements (ERVs and LINEs) have been proposed as cytosolic RNA
sensors that activate type I IFN responses [93]. Activated retroelements are also known to be a
source of long non-coding RNAs that have been recently attributed a role in activating antiviral re-
sponses and as potential tumor-specific novel epitopes that promote anticancer immunity [90].
Interestingly, SETDB1, a histone H3 lysine 9 (H3K9) methyltransferase, was recently reported
to help cancer cells to evade innate immune sensing of retrotransposons by inhibiting their acti-
vation [94]. Thus, retrotransposon restriction might also reflect the contribution of APOBEC to
tumor development, in accord with elevated A3 activity in virus-induced cancers (discussed ear-
lier). Interestingly, an association between retroelements and regulators of APOBECs has been
reported, where repression of tumor suppressors (p53 and RB1) leads to APOBEC activation
[95]. Inhibition of tumor suppressors also induces stalling of replication forks and generates
ssDNA [96]. These observations suggest a possible shared pathway that might be implicated
in the overexpression of APOBECs and retroelements in cancer and viral infections. A3A and
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A3G RNA-editing activity can be promoted by inflammation and hypoxia [97]. A3G was reported
to induce glycolysis and promote remodeling in leukemia and lymphoma cells, and also promote
cancer proliferation [97]. Furthermore, A3A RNA editing was also recently suggested to modulate
and amplify proinflammatory responses, and to regulate M1 polarization during viral infection and
in the tumor environment [46].
A perspective on the genomic and epigenomic contributions of APOBECs to
aging
The integrity of the genetic and epigenetic codes is compromised throughout the lifetime of an
organism. Aging, therefore, could be broadly defined as a progressive erosion of genomic and
epigenomic stability, damage accumulation, and functional decline.
MMR enhances APOBEC-mediated mutagenesis (see above), and A3 signatures were identified
in essential and neurodegenerative-associated genes. Omikli events showed twice as many
mutations as other age-related mutagenic events [81], suggesting that APOBECS are potentially
relevant to aging-related pathologies. Furthermore, C-to-T mtDNAmutations prevail during aging
and have been attributed to ssDNA availability (ROS and APOBEC substrate) and oxidative
damage [98,99]. As discussed earlier, A3s can induce mtDNA hypermutation during the differen-
tiation of neoplastic cells [100], and both share C-to-T signature biases (Figure 2). It is plausible,
therefore, that these processes influence each other through aging. Moreover, the process of
oxidative DNA damage removal has been tightly linked to trinucleotide repeat (TNR) expansion
(Box 2) [101], and disease progression associated with aging might be explained by its synergy
with APOBECs [102] (Box 2). ROS and APOBECs are known to copotentiate each other
(see above), adding not only to the TNR expansionmechanism but also to age-related pathologies
including cancer, whose propensity also increases with age.
The aging signatures (SBS1 and SBS5) are the largest, albeit constant, source of mutations
reported in healthy tissues and cancer [19]. Close behind, APOBECs represent an important
source of mutations in cancer [103]. APOBEC activity and kataegis have shown more dynamic
patterns in particular conditions. Because a gradual increase in APOBEC signatures during the
course of tumor evolution, and more broadly during inflammation, has been observed [20], it
stands to reason that time, or age, might correlate positively with APOBEC signatures. Likewise,
APOBECs are likely to contribute to late-cancer onset, progression, and tumor heterogeneity,
promoting worse outcomes in older patients and potentially triggering cancerous mechanisms
prior to tumorigenesis [104,105]. Inflammation, chronic or recurring, is thought to accelerate
the aging process [106,107]. It is therefore conceivable that APOBEC signatures increase
Box 2. APOBEC and the trinucleotide repeat expansion mechanism
The sensitivity of APOBECs for mesoscale genomic features has been recently highlighted by their preference for hairpin
structures as a substrate, including palindromic sequences which have recently been reported to show and increased
propensity for mutagenesis [126]. ssDNA exposed by R-loops are also prone to APOBECmutagenesis, and R-loop-induced
deamination of cytosines in CAG repeat tracts has been deemed responsible for nucleotide repeat instability [127]. Because
cotranscriptional and post-transcriptional R-loop formation can be induced and can generate mutations, genomic and
epigenomic APOBECeffects necessitate tight regulation. Any dysregulation, therefore,might have implications for APOBECs
in repeat expansion diseases. Pre-mRNA hairpin loops are also involved in some TNR diseases, and primary repeat motifs
involved in neurological disorders display APOBECC-to-U editing hallmarks [128]. Pre-mRNA hairpin loops are known to oc-
cur in TNR diseases; therefore, pre-mRNAmight serve as a template for cDNA generation by RNA reverse transcription and
lead to an expanded template to 'repair' the damage induced by APOBECs. Thus, it was proposed that APOBEC off-target
mutagenesis drives Ig SHM-like RNA reverse transcription responses and is partially responsible for repeat expansion dis-
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'episodically' following bouts of inflammation. This could potentially explain why some tissues in
our body are more vulnerable to the aging process than others, notably the immune and neuronal
compartments. Neurological disorders have been reported to develop simultaneously with aging.
RNA editing, via A1 and its RBM47 cofactor, can maintain microglia resting status, such as RNA
editing of Lamp2 transcripts. However, when A1 is inhibited in microglia of middle-aged mice it re-
sulted in central nervous system (CNS) proinflammation and neurodegeneration [108] (Figures 2
and 3). Interestingly, in other contexts, microglia autophagy and phagocytic/inflammatory dysfunc-
tion have also been linked to age-associated neurodegeneration [109].
The 'epigenetic clock' encoded by the DNA methylation landscape is thought to represent the
most promising molecular estimator of biological age and its associated phenotypes across
various species [110]. These epigenetic instabilities lead to damage accumulation, and can be
induced by environmental factors or errors in epigenetic transmission mechanisms or deregulation
of methylation maintenance mechanisms, such as DNMTs and TETs, thereby generating hetero-
geneous methylomes among the elderly [111]. Because global hypomethylation of CpG islands
is another shared feature between aging and cancer, and because APOBECs can demethylate
(via deamination) both epigenetic marks (5mC and 5hmC), it would be interesting in the future to
study the association between APOBEC activity/signatures and aging or aging-related
phenotypes, genetically and/or epigenetically (Figure 2). It would be tempting to speculate,
therefore, that aging might be an undesirable, albeit unavoidable, side-effect of antibody–antigen,
host–pathogen, and immune–tumor editing coevolution (Figure 4A).
Concluding remarks
In summary, APOBECs fulfill complex positive and negative roles (Figure 3) across fundamental
evolutionary processes through shared molecular mechanisms (Figure 4A). Following this trajec-
tory of research, it might be plausible to extrapolate an even broader role for APOBECs in
Box 3. Base editors in treatment and therapy
Single-nucleotide variants (SNVs) represent the majority of human disease-related genetic polymorphisms [131].
Correction of pathogenic SNVs requires high-precision genome-engineering technologies. Since the discovery of the
prokaryotic-derived clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated 9 (Cas9)
system it is possible to introduce targeted DNA DSBs at any given site. However, through error-prone non-homologous
end joining (NHEJ), non-specific insertions and deletions (indels) alter the gene sequence randomly [132]. That lack of
accuracy makes standard CRISPR/Cas9 unsuitable for precise editing. To overcome this limitation base editors (BEs)
have emerged. Cytosine base editors (CBEs) are a hybrid system merging the benefits of prokaryotic and mammalian
adaptive immunity [133–136]. By linking a nuclease-deficient Cas9 to a catalytically active cytosine deaminase, BEs can
create precise point mutations without causing unwanted DSBs or indels [131]. Within a narrow editing window of about
5 nt the target C is changed to a T. The DNA repair inhibitor uracil glycosylase inhibitor (UGI) is often included to enhance
C-to-T transition. A variety of different wild-type andmodified cytosine deaminases, including APOBECmembers and AID,
have been studied (reviewed in [137]). In addition to CBEs, adenosine base editors (ABEs) enable genomic A-to-T muta-
tions. ABEs use the engineered E. coli-derived tRNA adenosine deaminase [137]. Dual BEs and transversion CBEs are
further developments that enable simultaneous C-to-T/A-to-G and C-to-G mutations, respectively [138,139]. Engineering
of the Cas9 domain or replacement by other variants broadens their applicability [140].
The therapeutic potential of CBEs and ABEs has been reported in different genetic disorders (see Figure 4B in main text).
CBEs efficiently reversed T-to-C point mutations in vivo in genes that drive phenylketonuria, recessive hearing loss,
β-thalassemia, and Marfan syndrome, respectively [141–144]. Impressively, one-time injection of an ABE into mice
with Hutchinson–Gilford progeria was sufficient for complete disease remission [145]. Instead of correcting patho-
logic SNVs, BE can also insert point mutations into promoter regions to alter gene expression. That strategy has
been successfully applied in sickle cell disease to downregulate the BCL11A repressor protein [146]. BE-induced
nonsense mutations can further disrupt disease-related genes [147]. An indirect therapeutic benefit of BEs was
shown for cancer immunotherapy by improving multiplexed immune cell engineering [140]. Overall, BEs demon-
strate that AID and APOBECs can be applied in a programmable fashion to reverse pathogenic point mutations
or alter the expression of disease-related genes (see Figure 4B in main text).
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Outstanding questions
Do chronic and acute infections regulate
APOBECs activity in a different manner?
If chronic infections contribute to
persistent low APOBEC activity and the
accumulation of hypermutations, does
this contribute to cancer development
depending on additional environmental
factors? If acute infections occur in
cancer patients, does this potentiate
APOBECs hypermutation activity and
lead to cell death, thus restricting cancer
development?
Is APOBEC-associated genomic/
epigenomic editing a driver or passen-
ger in tumorigenesis? Do APOBECs
contribute to tumorigenesis and tumor
immunity positively, negatively, or
stochastically? What is the synergistic
contribution of DDR in this process?
How does the epigenomic landscape
affect APOBEC activities, and what
feedback loops are involved? Can
APOBECs edit methyl-C in RNA?
Do APOBECs fulfill synergistic or
antagonistic functions with other
deaminases in aging and tumor
immunity?
Do APOBECs contribute to organismal
diversification in a similar manner to
their role in immune and cancer
diversification (Figure 3A). If so, what
organism(s) could serve as a model.
Can gene editing through APOBECs
provide future avenues for corrective
or prophylactic interventions against
debilitating diseases and aging? Are
APOBECs a good therapeutic target
for small-molecule inhibitors or through
APOBEC activity mimicry? (Figure 3B).
organismal coevolution (Figure 4B), and a few studies have suggested such a possibility [5]. It is
important that we understand the intricate molecular differences between the positive and nega-
tive outcomes of editing such that we could selectively harness the former and limit the latter. For
example, APOBECA3B hypermutation has been associated with better outcomes in ovarian car-
cinoma [112]. In addition, A3B and A3A hypermutated breast cancer recently reported similar
positive clinical outcomes compared to less mutated cancer [113]. This unexpected feature
might be explained by an incremental increase in the neoantigenic load, thereby increasing anti-
cancer immunity [114]. For this reason it was recently proposed that APOBECsmay play a role as
a sensitizing system to improve chemotherapeutic treatments [115] (Figure 3). This novel thera-
peutic approach relies on actively driving mutations to generate novel neoepitopes presented
by tumor cells and thus prime antitumor T cells to make tumors susceptible to immunotherapy
[116]. A3B has also been postulated as a potential target for future therapeutic approaches
[117]. A3B is known to be upregulated by temozolomide, a common chemotherapy in glioblas-
toma [118]. Estrogen was recently reported to sensitize GBM cells to temozolomide chemother-
apy through estrogen receptor β (ER-β) by modulating DDR signaling pathways and diminishing
DNA repair, leading to apoptosis [117]. These events might be complemented and explained by
the action of A3B (Figure 3). The beneficial and detrimental features of APOBECs thus place them
as precise editors and therapeutic targets (Figure 4B). For this reason there is an urgent need to
better understand their regulation and mechanisms of action to enhance their biotechnological
applications (Box 3 and see Outstanding questions).
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